Kahr Bio Australia Pty
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kahr Bio Australia Pty sits in the upper half of US sponsors by registered trial count (#7,390 of 15,751 sponsors by registered trial count).
Kahr Bio Australia Pty: 1 sponsored US clinical trial, 1 recruiting.
Kahr Bio Australia Pty sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colorectal Cancer, with 1 trials.
Mid-pack sponsor footprint
Kahr Bio Australia Pty is in the upper half of sponsors by trial count (#7,390 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Kahr Bio Australia Pty pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Colorectal Cancer (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.